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Five Ethical Questions for SCNT Stem Cell 
Research 
Ronald M. Green* 
In August 2000, I received a phone call from Michael 
West, President and Chief Scientific Officer of Advanced Cell 
Technology (ACT), a small Massachusetts biotech company.  
West told me that ACT was about to embark on a program of 
research involving the use of somatic cell nuclear transfer 
(SCNT), also called therapeutic or research cloning, for the 
purpose of creating immunologically compatible embryonic 
stem cell lines.  He wanted to know whether I was interested 
in serving as Chair of an Ethics Advisory Board (EAB) that 
ACT was setting up to provide guidance for its research. 
Thus began an adventure that continues to occupy my 
time seven years later.  Like all adventures, it has had its 
emotional highs and lows: moments of exhilarating 
accomplishment and others of seeming failure.  Among them: 
the year-long collaborative effort of setting up the world’s first 
SCNT research egg donor program and watching the first eggs 
arrive for cloning experiments;1 the November 2001 
announcement of the creation of the world’s first cloned 
human embryo;2 and then days later, a bitter controversy over 
whether the announcement was premature in terms of its 
 ©  2008 Ronald M. Green. 
 * Ronald Green, Ph.D., is Eunice and Julian Cohen Professor for the 
Study of Ethics and Human Values, Dartmouth College; Director, Ethics 
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 1. Scientists Allege U.S. Losing Lead in Stem Cell Research; Advanced 
Cell Technology Generated Stem Cell Embryos in 2003, but Lack of Federal 
Funding Hampered Progress, BUS. WIRE, Nov. 23, 2005, http://findarticles. 
com/p/articles/mi_m0EIN/is_2005_Nov_23/ai_n15868043. 
 2. Jose B. Cibelli et al., Rapid Communication: Somatic Cell Nuclear 
Transfer in Humans: Pronuclear and Early Embryonic Development, E-
BIOMED: J. REGENERATIVE MED., Nov. 26, 2001, at 25, 25, http://www. 
liebertonline.com/doi/abs/10.1089/152489001753262168; Jose B. Cibelli et al., 
The First Human Cloned Embryo, SCI. AM., Jan. 2002, at 44, 45. 
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significance.3 
From 2002 to 2004, the Bush Administration threatened 
to ban SCNT research.  The Republican-dominated Congress 
eliminated the trickle of venture capital funding that kept 
ACT afloat.4  These hostilities forced the termination of the 
expensive therapeutic cloning program and impaired ACT’s 
ability to meet its payroll expenses, leading some key 
researchers to seek positions elsewhere.  In February 2004, 
there was combined disappointment and excitement when 
Korea’s Woo Suk Hwang announced that he had been able to 
derive lines of stem cells using the SCNT procedure.5  The 
disappointment derived from the awareness that the Koreans 
had accomplished what was just beyond ACT’s reach, given its 
cash-starved and politically harassed circumstances.  The 
excitement came in the “I told you so” moment when Hwang’s 
work appeared to vindicate ACT’s commitment to therapeutic 
cloning research.  Working beyond the reach of the Bush 
Administration, the Koreans had done it. 
Then, more disappointment and excitement came a year 
later when Hwang’s systematic fraud was revealed and his 
findings were discredited.6  This episode tarnished all stem 
cell research and heartened its critics.  But the goal still 
beckoned, and the experience ACT and its EAB had developed 
was once again of value.  Investors returned and the race was 
on. 
As I review the highs and lows of this adventure, I am 
struck by how many additional small achievements and 
setbacks there are to recount.  In meeting after meeting, the 
EAB has been confronted by the many novel ethical questions 
this research involves.  It has had to answer these questions 
in the context of an ongoing research program, in some cases 
with the safety of research participants at issue.  This article 
details five of the most challenging questions that the EAB 
has had to address: (1) what the correct name is for ACT’s 
 3. News & Comment, “Cloned” Human Embryo Sparks Reaction, 23 
TRENDS PHARMACOLOGICAL SCI. 58, 58 (2002). 
 4. Carol Ezzell, Cloning and the Law, SCI. AM., Jan. 2002, at 51. 
 5. Woo Suk Hwang et al., Evidence of a Pluripotent Human Embryonic 
Stem Cell Line Derived from a Cloned Blastocyst, 303 SCIENCE 1669, 1669 
(2004). 
 6. Lori Gruen, Oocytes for Sale?, 38 METAPHILOSOPHY 285, 304 (2007). 
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research; (2) whether SCNT research is ethically appropriate; 
(3) what the entity produced by SCNT is called and its moral 
status; (4) whether it is ethical to financially compensate 
women who provide eggs; and (5) whether there are 
alternatives that reduce or eliminate the morally questionable 
aspects of SCNT research. 
1. WHAT IS THE APPROPRIATE NAME FOR ACT’S 
RESEARCH? 
It is a measure of how controversial this whole area is 
that the seemingly trivial question of what to call ACT’s 
research occasions dispute.  From the start, ACT’s EAB 
identified its program as “therapeutic cloning” research.  This 
term was already used to distinguish cloning aimed at the use 
of SCNT technology to create immunologically compatible 
stem cells from reproductive cloning, the use of SCNT to 
create a child.  Nevertheless, voices were immediately raised 
criticizing this name.  In its July 2002 report, Human Cloning 
and Human Dignity, the Bush-appointed President’s Council 
on Bioethics (PCBE) replaced “therapeutic cloning” with the 
term “cloning for biomedical research.”7  It did so for two 
reasons.  First, the term was changed because Council 
members believed that the distinction between reproductive 
and therapeutic cloning was inaccurate, since all cloning 
involved the creation or reproduction of a human being.8  
Second, because, in the words of the report, while “[t]he act of 
cloning embryos may be undertaken with healing motives . . . 
it is not in itself an act of healing or therapy.  The 
beneficiaries of any such acts of cloning are, at the moment, 
hypothetical and in the future.”9  Both of these objections are 
questionable.  The claim that “all cloning is reproductive”10 
reflects a strong position on the nature and moral status of 
entities produced by SCNT cloning.  The elimination of the 
use of the term “therapy” is tendentious because it is quite 
obvious that the therapeutic benefits of this research lay in 
the future.  Nevertheless, these objections are not surprising 
from a Council that would ultimately take the unprecedented 
 7. THE PRESIDENT’S COUNCIL ON BIOETHICS, HUMAN CLONING AND 
HUMAN DIGNITY: AN ETHICAL INQUIRY 44–45 (2002). 
 8. Id. at 44. 
 9. Id. 
 10. Id. 
GREEN R. FIVE ETHICAL QUESTIONS FOR SCNT STEM CELL RESEARCH. MINN. J.L. SCI. & 
TECH. 2008;9(1):131-144.  
134 MINN. J.L. SCI. & TECH. [Vol. 9:1 
 
                                                          
 
step of proposing to criminalize this whole area of scientific 
research by recommending a four-year moratorium on it.11 
2. IS THIS RESEARCH ETHICALLY APPROPRIATE? 
That the members of ACT’s EAB chose to provide ethical 
guidance for the conduct of this research illustrates that all of 
those who signed on to the project believed, in principle, that 
therapeutic cloning research can be ethically conducted.  That 
judgment rested on three main convictions. 
First, the EAB believed that therapeutic cloning research 
has lifesaving potential and could dramatically address 
urgent medical needs.  Many of the disease conditions that 
remain without adequate therapies or cures are disorders 
caused by cell death or degeneration.  This includes both 
juvenile and late-onset diabetes, Parkinson’s disease, 
osteoporosis, skin and bone injuries, heart disease, and a host 
of neurological and neuronal disorders and injuries.12  Stem 
cell research offers new approaches to treating these 
conditions.  But what many regard as the most promising line 
of development, human embryonic stem cell research, still 
does not resolve the problem of tissue rejection.  This rejection 
is because stem cells from an embryo are perceived by the 
recipient’s body as foreign tissue.13  Medications could be used 
to prevent rejection, but they carry a steep price: increasing 
susceptibility to infections and cancers.14  Therapeutic cloning 
promises all of the benefits of embryonic stem cell research 
plus a solution to the problem of rejection.15  By creating cells 
or tissues for which the recipient provides the somatic cell 
nucleus for the cloning procedure, it is possible to generate 
immunologically compatible tissue or organs.16 
The viability of this approach was demonstrated by a 
proof-of-principle experiment conducted by ACT scientists 
 11. Id. at 205. 
 12. Robert P. Lanza et al., The Ethical Validity of Using Nuclear 
Transfer in Human Transplantation, 284 JAMA 3175, 3175 (2000) 
[hereinafter Lanza, Ethical Validity]. 
 13. Id. 
 14. Jennifer Couzin, Gently Soothing a Savage Immune System, 296 
SCIENCE 456, 456–57 (2002). 
 15. Lanza, Ethical Validity, supra note 12, at 3175. 
 16. Id. 
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working with researchers from Harvard, the Mayo Clinic, and 
the University of Miami.17  In this experiment, bovine renal 
tissue was created through a cloning procedure that began 
with the body cells of one cow and the enucleated egg of a 
second cow.18  Samples of the resulting cloned tissue were 
then attached to microtubules and plastic bladders.19  Some of 
these renal constructs were inserted under the skin of the 
original cell donor cow while others were inserted under the 
skin of control cows that had donated neither the original 
somatic cell nor the egg.20  When subsequently removed from 
the animals’ bodies for examination, the constructs inserted 
into control cows evidenced rejection and necrosis.21  The 
tissue of the constructs removed from the original cell donor 
cow was pink and perfused.22  Amazingly, these cells also 
produced urine that collected in the plastic bladder.23  Here 
were miniature, immunologically compatible kidneys.  This 
experiment graphically illustrates the scientific promise of 
therapeutic cloning research.24 
A second factor supporting EAB’s judgment about the 
moral acceptability of this research was its agreement that 
the moral status of the entity created by the SCNT procedure 
was, at most, identical to a fertilized human egg (or early 
embryo).  The EAB did not have a moral problem with the 
creation of SCNT embryos because it was of the opinion that 
sexually produced embryos could be used in potentially 
lifesaving research, whether the embryo was left over from 
infertility procedures or deliberately created for the purpose.  
The EAB believed that if it was permissible to create 
supernumerary embryos in in vitro fertilization (IVF) for 
reproductive purposes, it was also permissible to create 
embryos for lifesaving research.  Some EAB members further 
believed that the SCNT embryo has even less moral status 
 17. Robert P. Lanza et al., Generation of Histocompatible Tissues Using 
Nuclear Transplantation, 20 NATURE BIOTECHNOLOGY 689 passim (2002). 
 18. Id. at 694. 
 19. Id. 
 20. Id. 
 21. Id. at 690. 
 22. Id. at 692. 
 23. Id. 
 24. Although this experiment is illustrative, “[b]ecause the cloned cells 
were derived from early-staged fetuses, this approach is not an example of 
therapeutic cloning and would not be undertaken in humans.” Id. at 689. 
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than the early, sexually produced embryo. 
Third, and finally, while all the members of the EAB 
shared the widely held view that for safety reasons alone it 
would be unethical to produce a child by means of cloning, no 
member believed this research would significantly hasten the 
advent of reproductive cloning or that refraining from this 
research would prevent reproductive cloning.  Members 
understood that breakthroughs in therapeutic cloning 
techniques might contribute to the work of those seeking to 
accomplish reproductive cloning, but they believed that 
anyone bent on the latter would eventually be able to 
accomplish it with or without the help of therapeutic cloning 
researchers.  To explain through an analogy: abstaining from 
therapeutic cloning research in order to prevent reproductive 
cloning research would amount to avoiding giving a baby a 
bath because of the remote possibility of harming the baby. 
3. WHAT SHOULD WE CALL THE ENTITY PRODUCED BY 
SCNT (I.E., CLONING) AND WHAT IS ITS MORAL 
STATUS? 
Is the immediate result of human SCNT (i.e., cloning) a 
human embryo?  Is it a product of human reproduction, as the 
PCBE maintained?  If so, does it have the same moral status 
(whatever that status might be) as the embryo produced when 
a human sperm fertilizes a human egg?  Here again we have a 
terminological question that conceals powerful moral 
disagreements. 
To some people, it is obvious that the SCNT unit is 
morally equivalent to a human embryo.  It has a full 
complement of chromosomes as well as the potential to 
develop into an adult being.25  For these people, it is 
irrelevant that this potential requires intensive technological 
intervention and that it may have developmental potential 
significantly inferior to that of a sexually fertilized egg.26  
Embryos acquired from IVF also require intensive 
technological intervention, and scientific advances are likely 
to significantly reduce the current high mortality of SCNT 
 25. THE PRESIDENT’S COUNCIL ON BIOETHICS, supra note 7, at 153. 
 26. Id. at 156. 
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units.27  The mere chance that an entity could become a child, 
the critics maintain, should lead one to place it on a par with 
the product of fertilization.28 
Not everyone agrees.  During the EAB’s initial debates, 
one of its scientist members surprised the other members by 
launching into what can only be called an “ode to 
fertilization.”  She said that while working in reproductive 
medicine for many years, she never lost her sense of awe at 
watching a sperm fertilize an egg.  But she insisted that for 
her, the SCNT process had none of this sanctity.  It was an 
entirely artificial process and it could be arrested for research 
purposes as readily as it had been begun.  In a subsequent 
letter to a scientific journal, this colleague proposed a new 
name for the product of SCNT.29  She would call it an 
“ovasome,” or egg-body.30  This term, she believed, better 
described the very limited moral importance of what SCNT 
researchers were doing.31 
Whatever this entity is called, and however its moral 
status is assessed in relation to the sexually produced embryo, 
in no case would it rank higher.  Hence, individuals willing to 
use or create embryos for research purposes should be willing 
to support therapeutic cloning research.  For a more extensive 
treatment of this issue and defense of using human embryos 
in lifesaving research or research of outstanding biomedical 
value, one might look at the 1994 Report of the National 
Institute of Health Human Embryo Research Panel.32 
4. IS IT ETHICAL TO PAY WOMEN TO PROVIDE EGGS 
FOR THIS RESEARCH? 
Therapeutic cloning research requires an abundant 
supply of eggs.  In the case of Dolly the sheep, it took 277 
nuclear transfers to produce one viable embryo.33  While 
 27. Id. at 137. 
 28. Id. at 152–57. 
 29. Ann A. Kiessling, In the Stem-cell Debate, New Concepts Need New 
Words, 413 NATURE 453, 453 (2001). 
 30. Id. 
 31. Id. 
 32. NAT’L INST. OF HEALTH, REPORT OF THE HUMAN EMBRYO RESEARCH 
PANEL (1994). 
 33. DEP’T OF HEALTH, STEM CELL RESEARCH: MEDICAL PROGRESS WITH 
RESPONSIBILITY 24 (2000), available at http://www.dh.gov.uk/ 
PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/Publ
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technical advances may reduce this ratio, a viable therapeutic 
cloning research program still requires over a dozen egg 
donors to have even a chance at producing a stem cell line.34 
Egg donation requires the use of powerful drugs that 
stimulate a woman’s ovaries to produce multiple mature 
follicles instead of the single fertilizable egg of a normal 
cycle.35  Although some studies have suggested that these 
medications do not create significant risks for healthy women, 
the safety of their repeated use has not been confirmed.36  The 
non-aqueous drugs are painful to administer (requiring 
repeated injection directly into the buttocks) and they can 
cause the intense emotional reactions usually associated with 
hormonal irregularities.37  There is also a very small (and 
largely preventable) risk of ovarian hyperstimulation, a life 
threatening overreaction to the drugs.38  In view of all these 
risks and burdens, why should women volunteer to provide 
eggs for research unless they are adequately compensated?  
The experience with reproductive egg donation is instructive.  
In the United States, reproductive egg donors are paid 
varying but substantial sums of money and there is an 
adequate supply of donors.39  Great Britain, in contrast, 
prohibits payment for reproductive and research donors and 
has suffered a virtual standstill in supply.40  In an effort to 
address this problem, the Human Fertilisation and 
Embryology Authority (HFEA), the agency that provides 
oversight for all infertility medicine and embryo research in 
icationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4065084&chk=Igqu. 
 34. Alan Boyle, Researchers Customize Stem-Cell Lines, MSNBC, May 
19, 2005, http://www.msnbc.msn.com/id/7904332/. 
 35. Robert E. Bristow & Beth Y. Karlan, Ovulation Induction, Infertility, 
and Ovarian Cancer Risk, 66 FERTILITY & STERILITY 499, 499 (1996). 
 36. Id. 
 37. Ronald M. Green, Open Forum: It’s Right to Pay Women Who Give 
Their Eggs for Research, S.F. CHRONICLE,  July 19, 2005, at B7 [hereinafter 
Green, It’s Right to Pay Women]. 
 38. Ronald M. Green, The Ethical Considerations, SCI. AM., Jan. 2002, 
at 48, 49 [hereinafter Green, Ethical Considerations]. 
 39. Id.; see also Gruen, supra note 6, at 296.  But see id. at 285 
(reporting a shortage of eggs in California following the 2004 ballot initiative 
prohibiting sale of oocytes for research purposes). 
 40. Press Release, Newcastle Univ. Press Office, ‘Egg Sharing’ Go-Ahead 
for Stem Cell Researchers (July 27, 2006), available at http://www.ncl.ac.uk/ 
press.office/press.release/content.phtml?ref=1154008083. 
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that country, has permitted egg-sharing programs, whereby 
women undergoing IVF can receive discounted services for 
offering some of their eggs to other women who need them for 
reproductive purposes.41  Last year, the HFEA expanded this 
permission to include research egg donation.42 
In 2005, an influential report by a committee of the 
National Academy of Sciences recommended against payment 
(beyond out-of-pocket expenses) for research egg donation.43  
In the wake of this, several states, including California and 
Massachusetts, passed laws prohibiting payment for eggs for 
research.44  Because both states have significant public or 
private commitments to therapeutic cloning research, these 
bans have had the effect of preventing this research from 
starting.  Since the passage of the Massachusetts law, despite 
expressions of interest from over one hundred women in 
response to advertising, ACT has been able to secure only one 
voluntary donor.45  This compares to over eighty women who 
donated eggs under the previous paid research donor 
program. 
Why, if payment is so clearly needed to facilitate 
research, do so many authorities oppose it?  Some of the 
answers given to this question do not withstand close scrutiny 
and may even proceed from sexist premises.  The view that 
women can be paid for eggs for reproductive but not research 
purposes may reflect the belief that maternally related 
sacrifices are somehow proper to women, whereas a 
commitment to science research is not.  Some fear that poor 
women and women of color will be disproportionately 
attracted to research egg donation since the mother’s genetics 
and accomplishments do not matter in this sphere as they do 
in the reproductive one.46  The concern is that such payments 
may constitute an “undue influence,” compromising women’s 
ability to provide free and informed consent and risking their 
 41. Id. 
 42. Id. 
 43. NAT’L ACAD. OF SCI, GUIDELINES FOR HUMAN EMBRYONIC STEM 
CELL RESEARCH 83 (2005). 
 44. Green, It’s Right to Pay Women, supra note 37. 
 45. Bijal Trivedi, Researchers Detour Around Stem-Cell Rules: Thwarted 
by Regulations on Egg Donation for Research, Scientists Craft New Ways to 
Manufacture Embryos, CHRONICLE OF HIGHER EDUC., Oct. 5, 2007, at 12. 
 46. Gruen, supra note 6, at 303. 
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health.47  But it can also be asked why women should be 
protected from their own decision-making and whether such 
attitudes reflect unjustified paternalism—or patriarchalism.48  
In a world where normal research volunteers are often paid 
for their participation in risky research, why should women be 
denied similar opportunities? 
An unpublished review of reports from the ACT research 
egg donors indicates that the more than eighty women who 
served in this capacity tended to express two equally 
significant reasons for doing so: (1) a desire to contribute to 
stem cell research and (2) a desire for the money.  Many of 
these women reported having family members who suffered 
from diseases like diabetes that stem cell therapies might 
address.  In view of this, the prohibition on payment becomes 
even more problematic.  Why should women who wish to 
contribute to research, but who need a financial incentive to 
overcome their natural reluctance to submit to a demanding 
drug regimen, be held to a purely altruistic standard? 
Seven years ago, ACT’s EAB asked all these questions 
regarding compensation for egg donors.  The EAB discussed—
and rejected—egg sharing on the grounds that it unwisely 
mixes the sensitive issue of infertility treatment with research 
donation.  If a women’s reproductive quest fails, will she come 
to regret and resent her decision to donate eggs for research 
purposes?  Will she harbor the view that researchers took the 
best of her eggs?  The EAB also carefully developed guidelines 
to protect women from harm.49  These guidelines covered 
everything from age limits, psychological testing, and 
reproductive history to safe estradiol levels.  In the end, the 
EAB concluded that a well-developed program was ethically 
and scientifically appropriate.  It is distressing that seven 
years down the line, as programs around the country renew 
their attention to therapeutic cloning, these lessons need to be 
learned all over again. 
 47. NAT’L ACAD. OF SCI., supra note 43, at 71. 
 48. Green, Ethical Considerations, supra note 38, at 49. 
 49. See Press Release, Advanced Cell Tech., Statement by the Ethics 
Advisory Board of Advanced Cell Technology (June 2, 2002), available at 
http://www.advancedcell.com/press-release/statement-by-the-ethics-advisory-
board-of-advanced-cell-technology) (“The ACT EAB has also established a 
rigorous program of informed consent for women who donate eggs for human 
therapeutic cloning research.”). 
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5. CAN THE SCNT PROCEDURE BE ALTERED TO 
REDUCE OR ELIMINATE ITS MORALLY QUESTIONABLE 
ASPECTS? 
Several technical ideas have been advanced to address 
some of the ethical questions raised by SCNT technology.  For 
example, it has been proposed to use animal oocytes to replace 
the use of human eggs in the cloning procedure.50  There have 
been reports of success with this approach, although they 
have not been replicated.51  Unfortunately, although the use 
of animal oocytes eliminates the problems associated with 
human egg donors, it raises additional problems associated 
with the production of animal-human chimeras or what have 
been termed “cybrids.”52  These include concerns ranging from 
the possibility that the resulting stem cells may be unsuitable 
for transplant and could introduce animal DNA or pathogens 
into the human population to the nightmarish possibility that 
chimeric embryos might be diverted for reproductive 
purposes.53  Ethically, this approach raises more questions 
than it answers. 
A more radical change in the SCNT procedure has 
recently been proposed as a way of eliminating the moral 
discomfort with human embryonic stem cell researched 
experienced by those who regard the early embryo as a human 
being. This proposal, known as Altered Nuclear Transfer 
(ANT) was made by William Hurlbut, a member of the 
PCBE.54  It involves using the standard SCNT cloning 
procedure for the purpose of stem cell derivation—with one 
notable difference.  In ANT, the somatic cell used for cloning 
is first genetically altered so as to impair the resulting SCNT 
unit’s developmental capability.55  Hurlbut states that 
 50. Michael Schirber, A Dash for Hare Eggs, 311 SCIENCE 317 (2006). 
 51. Id. 
 52. Id.; see also Constance Holden, Report Backs Interspecies Lines, 316 
SCIENCE 1683 (2007). 
 53. Schirber, supra note 50, at 317. 
 54. William B. Hurlbut, Altered Nuclear Transfer as a Morally 
Acceptable Means for the Procurement of Human Embryonic Stem Cells 
(2004) (working paper), available at 
http://www.bioethics.gov/background/hurlbut.html. 
 55. Alexander Meissner & Rudolf Jaenisch, Generation of Pluripotent 
NT-ES Cells from Cloned Cdx2 Deficient Blastocysts, 439 NATURE 212, 212 
(2006).  This was done experimentally by impairing the Cdx2 gene that is 
responsible for placental development.  Id.  Lacking a functioning copy of 
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because this modification is undertaken before the clonal 
embryo is even created, the resulting entity would have “no 
inherent principle of unity, no coherent drive in the direction 
of the mature human form, and no claim on the moral status 
due to a developing human life.”56  He prefers the term 
“clonal” or “biological artifacts” for these entities.57 
Unfortunately, it is by no means clear that many of the 
people who morally equate the early human embryo with a 
full human being will be satisfied with this strategy for 
producing immunologically compatible stem cells.  ANT 
embryos develop normally until Cdx2 function is required, at 
which point they die.58  This suggests that people with a high 
estimate of the status of early nascent human life might 
reasonably interpret this procedure as involving the 
deliberate creation of an impaired human being in order to 
justify destroying it.  In effect, they would see it as doing two 
wrongs in order to do a right. 
A simple example supports this objection.  If the early 
embryo is fully a human being, as the opponents of embryo 
destruction believe, how does ANT differ morally from the 
deliberate creation of an anencephalic infant as an organ 
donor?  Lacking a cerebrum, this child can also be said to have 
“no inherent principle of unity, no coherent drive in the 
direction of the mature human form, and no claim on the 
moral status due to a developing human life.”59  If we find 
such a proposal morally repugnant, it is not clear why an 
analogous impairment imposed on a “human being” at a much 
earlier stage is acceptable. 
CONCLUSION 
Despite the serious reverses represented by the Korean 
scandal, therapeutic cloning remains one of the most 
promising biomedical technologies before us.  As my tenure as 
Chair of ACT’s EAB indicates, I believe that none of the 
this gene, the NT unit cannot implant and develop.  If necessary, it might be 
possible to turn the Cdx2 gene on again in the resulting stem cells. 
 56. Hurlbut, supra note 54. 
 57. THE PRESIDENT’S COUNCIL ON BIOETHICS, supra note 7, at 275. 
 58. Douglas A. Melton et al, Altered Nuclear Transfer in Stem-Cell 
Research—A Flawed Proposal, 351 NEW ENG. J. MED. 2791, 2791 (2004). 
 59. Hurlbut, supra note 54. 
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ethical concerns resident in these five questions constitutes a 
reason for refusing to go forward with this research.  Whether 
we call the entity created by SCNT an embryo or an SCNT 
unit, that creation need not be given more—and probably 
should be given somewhat less—moral weight to it than is 
given to the early human embryo, which can responsibly be 
used to derive stem cell lines.  Payment for research oocytes 
seems to be fully justified and does not raise problematic, 
long-term issues.  Some people fear that the successful 
development of therapeutic cloning will create a vast market 
in human eggs that will lead to the exploitation of poor 
women.60  However, several promising technologies are on the 
horizon, including in vitro egg maturation and the 
development of oocytes from stem cells themselves that will 
obviate the need to call on large populations of egg donors.61  
Furthermore, therapeutic cloning is a “transitional” form of 
research.62  Once scientists better understand which 
components of egg cytoplasm remodel a cell’s nuclear DNA in 
the cloning context, they can use these purified cytoplasmic 
factors for direct cellular dedifferentiation and 
reprogramming. 
All of this suggests that research should be furthered.  
States like California and Massachusetts, where therapeutic 
cloning research is permissible, should repeal the bans on 
adequate compensation for research egg donors.63  Congress 
should also abandon its previous efforts to criminalize this 
research.64 
Seven years ago, when I accepted the leadership of ACT’s 
EAB, I nourished the hope that we would see clonally 
 60. See, e.g., Judy Norsigian, Egg Donation for IVF and Stem Cell 
Research: Time to Weigh the Risks to Women’s Health, DIFFERENT TAKES 
(Hampshire College Population & Development Program) Spring, 2005, at 1, 
3; Diane Beeson & Abby Lippman, Egg Harvesting for Stem Cell Research: 
Medical Risks and Ethical Problems, 13 REPROD. BIOMEDICINE 573, 573, 575 
(2006). 
 61. Nicholas Wade, Pennsylvania Researchers Turn Stem Cells to Egg 
Cells, N.Y. TIMES, May 2, 2003, at A28. 
 62. DEP’T OF HEALTH, supra note 33. 
 63. This does not preclude the need for more intensive animal research 
to increase the efficiency of the cloning procedure before we expose women to 
risk by seeking eggs from human donors. 
 64. See Gretchen Vogel, Science Policy: Cloning Bills Proliferate in U.S. 
Congress, 292 SCIENCE 1037 (2001); see, e.g., S. 1036, 110th Cong. (2007) (“A 
bill to amend the Public Service Act to Prohibit Human Cloning.”). 
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produced stem cells within a few years.  We almost did.  If it 
had not been for continual political meddling, that hope might 
have been realized.  It is now time for good science and good 
research ethics, not politics, to shape the future. 
